CoNotes

Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. We are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Our operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science.

We are developing products based on Transave’s proprietary liposomal technology designed specifically for lung delivery. Our focus is on reformulating off-patent, established drugs into unique liposomal technology – based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases.

(Source: Transave)